Slide 1: Bright Lights Conference, BIOLASE Technology, Inc.
BRIGHT LIGHTS CONFERENCE May 10th & 11th, 2011, New York City BIOLASE Technology, Inc. Federico Pignatelli, CEO, Chairman and Shareholder Fred Furry, CFO, VP Finance Dmitri Boutoussov, CTO, VP Engineering
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation may contain forward-looking statements that are based on our current expectations, estimates and projections about our industry as well as management's beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "e
Slide 3: Redefining Surgery in Dentistry and Medicine
Redefining Surgery in Dentistry and Medicine Conventional Surgical Devices: Scalpel, High Speed Drill, Electrosurge, Electric Bone Saws and Heat Generating Lasers How BIOLASE Changes That? The Science of WaterLase Years of engineering and research at BIOLASE led to the discovery that the Er,Cr:YSGG
Slide 4: Why BIOLASE WaterLase Technology in Dentistry?
Why BIOLASE WaterLase Technology in Dentistry?
Slide 5: Traditional Dentistry
Traditional Dentistry Traditional Dentistry The painting Cavadenti, the Tooth Puller, by Caravaggio, circa 1608
Slide 6: Progressive & Biological Hi-Tech Dentistry
5/10/2011 PAGE 6 Progressive & Biological Hi-Tech Dentistry Atraumatic Pediatric Tooth Extraction The aiming beam on the NEW WaterLase iPlus is green. This red beam featured in the previous generation of WaterLase products does not cut the tissue. Tissue is cut biologically, with water at the molecu
Slide 7: Making Dentistry Less Frightening
Making Dentistry Less Frightening Traditional Surgical Approach: Using the dental drill offers more of the same which is pain, local anesthetic, swelling, pain killers, micro-fractures and the potential for cross contamination. Progressive and Hi-tech Surgical Approach: Using WaterLase technology of
Slide 8: Technology Supported by Scientific Data
Technology Supported by Scientific Data 5/10/2011 PAGE 8 Substantial Data: The effectiveness of dental lasers is proven and well researched. Clinical data and peer- reviewed specialty journals substantiate the effectiveness of laser treatment in a wide variety of procedures.
Slide 9: Dental Schools Teaching WaterLase Technology
Some of the Dental Schools that are Teaching WaterLase Technology around the World
Slide 10: WaterLase High Speed Cutting
WaterLase High Speed Cutting 5/10/2011 PAGE 10
Slide 11: WaterLase vs. Drill
WaterLase vs. Drill 5/10/2011 PAGE 11
Slide 12: Why WaterLase Technology? No Pain, No Tissue Damage
Why WaterLase Technology? Because NO Pain, NO Tissue Damage & NO Risk of Cross-Contamination: WaterLase MD(tm) reduced E. faecalis 2.86 times more effectively than NaOCl3 1. Dental Burs and Endodontic Files: Are Routine Sterilization Procedures Effective?: Archie Morrison, DDS, MS, FRCD(C); Susan Co
Slide 13: Patent Portfolio Current Status
Current Status: As of December 2010, BIOLASE had 286 issued and pending patents, 70% of which are related to our core Er;Cr:YSGG technology and medical lasers. Filing costs and maintenance are closely monitored. Funding for redundant patents and patents with a low-probability for issuance are stoppe
Slide 14: Intellectual Property: Paths to Monetization
Paths to monetization: Internal development, licensing, and legal action against infringers. Analyses by IP rating firms and management have identified patent families with the greatest potential: Ophthalmology, specifically a medical treatment for Presbyopia, laser toothbrush, and flavored and ster
Slide 15: Foundation for a Rapid Recovery
Why a turnaround of BIOLASE today will be quicker and more effective than in the past: BIOLASE has a better organizational structure, better cost control, and more efficient & effective management than ever before. The BIOLASE brand is currently known by over 80% of North American dentists and is gr
Slide 16: How BIOLASE is Positioned
How BIOLASE is Positioned BIOLASE United States BIOLASE International Total: 12,200 Total: 5,100 Grand Total: 17,300 (CHART) (CHART) 2,700 2,400 5,500 6,700
Slide 17: Owning the Hard Tissue Dental Laser Market
Owning BIOLASE Means Owning the Hard Tissue Dental Laser Market... Biolase 80% Source: Biolase Technology Licensing Reports 5/10/2011 PAGE 17
Slide 18: The Overall Dental Laser Market
....and the Overall Dental Laser Market. Biolase 45% Source: iData Research Inc. 5/10/2011 PAGE 18 2009 US Dental Laser Market: Hard & Soft Tissue
Slide 19: Our Market Opportunity
Our Market Opportunity BIOLASE's current market penetration is less than 1.5% of the potential global market. 176,000 dentists in the US and Canada.1 Over 1.2 million dentists in 134 countries.2 17,300 systems in over 10,000 practices. Every 1% of further market penetration is equal to an opportunit
Slide 20: The Untapped Portion of the Market
The Untapped Portion of the Market How BIOLASE WaterLase technology can increase a dentist's patients by 33%. According to the ADA...nearly 25% of all Americans avoid dentists because they are afraid of dental drills and needles. There are 160,000 dentists currently serving a population of 300 milli
Slide 21: Global Opportunity in Emerging Dental Markets
Global Opportunity in Emerging Dental Markets North America 176,000 dentists 1 dentist / 1,900 population Western Europe 240,000 dentists 1 dentist / 1,800 population Latin America 298,000 dentists 1 dentist / 5,600 population Eastern Europe 120,000 dentists 1 dentist / 4,000 population Middle East
Slide 22: Emerging Market Opportunities
Emerging Market Opportunities 5/10/2011 PAGE 22 Private Dental Office in China. California Suburb? No...China.
Slide 23: The Value of Technology
The Value of Technology 5/10/2011 PAGE 23 Dental Lasers: Allows dentists to perform their current daily procedures more efficiently plus perform a wide variety of dental procedures they otherwise may be referring out of their practices. Cone Beam 3-D Dental Imaging: Provides a high-definition, digit
Slide 24: Ophthalmology and Medical Applications
Ophthalmology: BIOLASE currently holds 10 issued and 19 pending U.S. and International patents in four patent families in the field ophthalmology. These patents give BIOLASE a wide range of applications and coverage in the field. Management is currently evaluating spinning- off of this technology in
Slide 25: Current Line of BIOLASE Products
Current Line of BIOLASE Products 5/10/2011 PAGE 25 All-tissue dental lasers: Our all-tissue lasers include our new flagship laser, the revolutionary WaterLase iPlus, and the WaterLase MD Turbo, an entry level all-tissue laser. Diode soft-tissue dental lasers: Our soft tissue lasers include the ezLas
Slide 26: Global Leader in Dental Lasers
Global Leader in Dental Lasers Over 17,300 laser systems sold to over 10,000 dental practices in over 50 countries worldwide. We have over 160 employees worldwide We have sales offices in the U.S., Floss (Germany), Madrid (Spain) and Shanghai (China) with expansion planned in Mumbai (India), Dubai (
Slide 27: Operations
Operations 5/10/2011 PAGE 27 Manufacturing and Research & Development Our 57,000 sq. ft. facility houses administrative, sales, marketing, customer care, training, R&D and manufacturing. It is ISO 9001 certified and FDA GMP with clean room operations. Nearly 100% of our components and subassemblies
Slide 28: Management and Employees as Stakeholders
Management and Employees: BIOLASE's entire executive team holds options to purchase common stock. Further, in December 2010, the Board of Directors granted approximately 1.5 million stock options to ALL of the employees of the Company. These options have a strike price of $2 and have made all employ
Slide 29: Chart & Financial History
5/10/2011 PAGE 29 Volume: Millions of Shares 0.5 1.0 Chart & Financial History 20 15 10 5 BLTI SHARE PRICE Guidance 62.5 1994-2006 Pignatelli Chairman of the Board Exclusive distribution partnership with Henry Schein Aug 2006-Aug 2010 Aug 2010-Present Pignatelli CEO & Board Chairman 1998 FDA Clearan
Slide 30: BLT!
BLT! cL PG PAT curr, BIOLASETechnology Colgate-Pakmolive Procter Gamble PalomarMedTech Cuteraine $550 $9585 sear $1394 se 23 27 23 37 20 Si5iM 187 167 400% Stock 278% 3.12% 20.0% 947% 894% 580% BIOLASE
Slide 31: Bright Lights Conference, BIOLASE Technology, Inc.
BRIGHT LIGHTS CONFERENCE May 10th & 11th, 2011, New York City BIOLASE Technology, Inc. Federico Pignatelli, CEO, Chairman and Shareholder Fred Furry, CFO, VP Finance Dmitri Boutoussov, CTO, VP Engineering